1. Sadock BJ, Sadock VA. Kaplan and Sadock's Comprehensive Textbook of Psychiatry. 8th ed. Philadelphia: Lippincott Williams & Wilkins; 2005.
2. Gulec C, Koroglu E. Basic Psychiatry Textbook. Ankara: Physicians Broadcasting Union; 1997.
3. Michael H, Ebert M, Loosen T, Nurcombe B. Current Diagnosis and Treatment in Psychiatry. New York: McGraw Hill; 2003.
4. Rothermundt M, Peters M, Preehn JH, Arolt V. S100B in Brain damage and neurodegenaration. Microsc Res Tech 2003;60:614-632. PMID:
12645009.
5. Adami C, Sorci G, Blasi E, Agneletti AL, Bistoni F, Donato R. S100B expression in and effects on microglia. Glia 2001;33:131-142. PMID:
11180510.
6. Whitaker-Azmitia PM, Murphy R, Azmitia EC. Stimulation of astroglial 5-HT1A receptors releases the seretonergic growth factor, protein S100, and alters astroglial morphology. Brain Res 1990;528:155-158. PMID:
2245332.
7. Tramonita AC, Tramonita F, Bobermin LD, Zanotto C, Souza DF, Leite MC, et al. Secretion of S100B, an astrocyte-derived neurotrophic protein, is stimulated by fluoxetine via a mechanizm independent of serotonin. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:1580-1583. PMID:
18582527.
8. Bock N, Koc E, Alter H, Roessner V, Becker A, Rothenberger A, et al. Chronic fluoxetine treatment changes S100B expression during postnatal rat brain development. J Child Adolesc Psychopharmacol 2013;23:481-489. PMID:
24024533.
9. Grabe HJ, Ahrens N, Rose HJ, Keller C, Freyberger HJ. Neurotrophic factor S100 beta in major depression. Neuropsychobiology 2001;44:88-90. PMID:
11490177.
10. Rothermundt M, Misler U, Arolt V, Peters M, Leadbeater J, Wiesmann M, et al. Increased S100B blood levels in unmedicated and treated schizophrenic patients are correlated with negative symptomatology. Mol Psychiatry 2001;6:445-449. PMID:
11443531.
11. Schroeter ML, Abdul-Khaliq H, Krebs M, Diefenbacher A, Blasig IE. Serum markers support disease-specific glial pathology in major depression. J Affect Disord 2008;111:271-280. PMID:
18430474.
12. Schroeter ML, Steiner J. Elevated serum levels of the glial marker protein S100B are not specific for schizophrenia or mood disorders. Mol Psychiatry 2009;14:235-237. PMID:
19229202.
13. Steiner J, Bogerts B, Schroeter ML, Bernstein HG. S100B protein in neurodegenerative disorders. Clin Chem Lab Med 2011;49:409-424. PMID:
21303299.
14. Schroeter ML, Sacher J, Steiner J, Schoenknecht P, Mueller K. Serum S100B represents a new biomarker for mood disorders. Curr Drug Targets 2013;14:1237-1248. PMID:
23701298.
15. Gos T, Schroeter ML, Lessel W, Bernstein HG, Dobrowolny H, Schiltz K, et al. S100B-immunopositive astrocytes and oligodendrocytes in the hippocampus are differentially afflicted in unipolar and bipolar depression: a postmortem study. J Psychiatr Res 2013;47:1694-1699. PMID:
23896207.
16. Akhisaroglu M, Manev R, Akhisaroglu E, Uz T, Manev H. Both aging and chronic fluoxetine increase S100B content in the mouse hippocampus. Neuroreport 2003;14:1471-1473. PMID:
12960766.
17. Rong H, Wang G, Liu T, Wang H, Wan Q, Weng S. Chronic mild stress induces fluoxetine-reversible decreases in hippocampal and cerebrospinal fluid levels of the neurotrophic factor S100B and its specific receptor. Int J Mol Sci 2010;11:5310-5322. PMID:
21614209.
18. Hetzel G, Moeller O, Evers S, Erfurth A, Ponath G, Arolt V, et al. The astroglial protein S100B and visually evoked event-related potentials before and after antidepressant treatment. Psychopharmacology (Berl) 2005;178:161-166. PMID:
15316717.
19. Dietrich DE, Hauser U, Peters M, Zhang Y, Wiesmann M, Hasselmann M, et al. Target evaluation processing and serum levels of nerve tissue protein S100B in patients with remitted major depression. Neurosci Lett 2004;354:69-73. PMID:
14698484.
20. Graeff FG, Zangrossi H Jr. The dual role of serotonin in defense and the mode of action of antidepressants on generalized anxiety and panic disorders. Cent Nerv Syst Agents Med Chem 2010;10:207-217. PMID:
20528764.
21. Deakin JF, Graeff FG. 5-HT and mechanisms of defence. J Psychopharmacol 1991;5:305-315. PMID:
22282829.